fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Pamidronate disodium

All injection strengths: not a benefit

Pamidronate Disodium for Injection · DIN 02246597 · 3 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Pamidronate Disodium for Injection · DIN 02246597 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2019-08-30 Health Canada: Marketed since 2015-07-07 · brand PAMIDRONATE DISODIUM FOR INJECTION · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 3 MG/ML · company Fresenius kabi canada ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pamidronate Disodium for Injection: Formulary list price $86.78 per unit (the source does not state the unit; exact figure $86.7800). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246597)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246597). DIN 02246597: Pamidronate Disodium for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000562; group id 947; item number 2251; lccId None; manufacturer id FKC Source form: Inj Sol-10mL Vial; strength: 3mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $86.7800; ministry $86.7800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246597 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70784
Interchangeable products
Aredia · DIN 02059762 · not recorded Pamidronate Disodium Omega · DIN 02249669 · $86.7800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246597
Shortage record checked October 6, 2026

Pamidronate Disodium Omega · DIN 02249677 · 6 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Pamidronate Disodium Omega · DIN 02249677 Manufacturer: Omega Laboratories Ltd.; listing date 2011-12-15 Health Canada: Marketed since 2006-05-24 · brand PAMIDRONATE DISODIUM OMEGA 6 MG/ML · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 6 MG/ML · company Omega laboratories limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pamidronate Disodium Omega: Formulary list price $176.70 per unit (the source does not state the unit; exact figure $176.7000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02249677)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02249677). DIN 02249677: Pamidronate Disodium Omega Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000563; group id 947; item number 2252; lccId None; manufacturer id OMG Source form: Inj Sol-10mL Vial; strength: 6mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $176.7000; ministry $176.7000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02249677 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73448
Interchangeable products
Aredia · DIN 02059770 · not recorded Pamidronate Disodium for Injection · DIN 02246598 · $176.7000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249677
Shortage record checked October 6, 2026

Pamidronate Disodium for Injection · DIN 02246598 · 6 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Pamidronate Disodium for Injection · DIN 02246598 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2019-08-30 Health Canada: Marketed since 2015-07-07 · brand PAMIDRONATE DISODIUM FOR INJECTION · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 6 MG/ML · company Fresenius kabi canada ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pamidronate Disodium for Injection: Formulary list price $176.70 per unit (the source does not state the unit; exact figure $176.7000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246598)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246598). DIN 02246598: Pamidronate Disodium for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000563; group id 947; item number 2252; lccId None; manufacturer id FKC Source form: Inj Sol-10mL Vial; strength: 6mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $176.7000; ministry $176.7000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246598 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70785
Interchangeable products
Aredia · DIN 02059770 · not recorded Pamidronate Disodium Omega · DIN 02249677 · $176.7000
Shortage status: resolved shortage (ended May 1, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246598
Shortage record checked October 6, 2026

Pamidronate Disodium Omega · DIN 02249685 · 9 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Pamidronate Disodium Omega · DIN 02249685 Manufacturer: Omega Laboratories Ltd.; listing date 2011-12-15 Health Canada: Marketed since 2005-07-27 · brand PAMIDRONATE DISODIUM OMEGA 9 MG/ML · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 9 MG/ML · company Omega laboratories limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pamidronate Disodium Omega: Formulary list price $260.33 per unit (the source does not state the unit; exact figure $260.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02249685)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02249685). DIN 02249685: Pamidronate Disodium Omega Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000564; group id 947; item number 2253; lccId None; manufacturer id OMG Source form: Inj Sol-10mL Vial; strength: 9mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $260.3300; ministry $260.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02249685 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73449
Interchangeable products
Aredia · DIN 02059789 · not recorded Pamidronate Disodium for Injection · DIN 02246599 · $260.3300
Shortage status: resolved shortage (ended October 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249685
Shortage record checked October 6, 2026

Pamidronate Disodium for Injection · DIN 02246599 · 9 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Pamidronate Disodium for Injection · DIN 02246599 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2019-08-30 Health Canada: Marketed since 2015-07-09 · brand PAMIDRONATE DISODIUM FOR INJECTION · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 9 MG/ML · company Fresenius kabi canada ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pamidronate Disodium for Injection: Formulary list price $260.33 per unit (the source does not state the unit; exact figure $260.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246599)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246599). DIN 02246599: Pamidronate Disodium for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000564; group id 947; item number 2253; lccId None; manufacturer id FKC Source form: Inj Sol-10mL Vial; strength: 9mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $260.3300; ministry $260.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246599 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70786
Interchangeable products
Aredia · DIN 02059789 · not recorded Pamidronate Disodium Omega · DIN 02249685 · $260.3300
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246599
Shortage record checked October 6, 2026

Aredia · DIN 02059762 · 3 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-23 — choose a marketed DIN from the same-category list.Discontinued February 23, 2016 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-23 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2016-02-23 — choose a marketed DIN from the same-category list.
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Aredia · DIN 02059762 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-07-12 Health Canada: Cancelled post market since 2016-02-23 · brand AREDIA 30MG · ATC M05BA03 PAMIDRONIC ACID · form Powder for solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 30 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Aredia: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02059762)

Source record
DIN 02059762: Aredia Raw flags: sec3=Y, sec3b=Y Item: 920000562; group id 947; item number 2251; lccId None; manufacturer id NOV Source form: Inj Sol-10mL Vial; strength: 3mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02059762 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19020
Interchangeable products
Pamidronate Disodium Omega · DIN 02249669 · $86.7800 Pamidronate Disodium for Injection · DIN 02246597 · $86.7800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02059762
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 23, 2016 — choose a marketed DIN from the same-category list.

Pamidronate Disodium Omega · DIN 02249669 · 3 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-29 — choose a marketed DIN from the same-category list.Discontinued July 29, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-29 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2026-07-29 — choose a marketed DIN from the same-category list.
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Pamidronate Disodium Omega · DIN 02249669 Manufacturer: Omega Laboratories Ltd.; listing date 2011-12-15 Health Canada: Cancelled post market since 2026-07-29 · brand PAMIDRONATE DISODIUM OMEGA 3 MG/ML · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 3 MG/ML · company Omega laboratories limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pamidronate Disodium Omega: Formulary list price $86.78 per unit (the source does not state the unit; exact figure $86.7800). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02249669)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02249669). DIN 02249669: Pamidronate Disodium Omega Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000562; group id 947; item number 2251; lccId None; manufacturer id OMG Source form: Inj Sol-10mL Vial; strength: 3mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $86.7800; ministry $86.7800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02249669 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73447
Interchangeable products
Aredia · DIN 02059762 · not recorded Pamidronate Disodium for Injection · DIN 02246597 · $86.7800
Shortage status: active shortage (reported January 1, 2013, last updated October 5, 2017) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249669
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 29, 2026 — choose a marketed DIN from the same-category list.

Aredia · DIN 02059770 · 6 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2001 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-30 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2001-07-30 — choose a marketed DIN from the same-category list.
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Aredia · DIN 02059770 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-07-12 Health Canada: Cancelled post market since 2001-07-30 · brand AREDIA · ATC M05BA03 PAMIDRONIC ACID · form Powder for solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 60 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Aredia: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02059770)

Source record
DIN 02059770: Aredia Raw flags: sec3=Y, sec3b=Y Item: 920000563; group id 947; item number 2252; lccId None; manufacturer id NOV Source form: Inj Sol-10mL Vial; strength: 6mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02059770 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19019
Interchangeable products
Pamidronate Disodium Omega · DIN 02249677 · $176.7000 Pamidronate Disodium for Injection · DIN 02246598 · $176.7000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02059770
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2001 — choose a marketed DIN from the same-category list.

Aredia · DIN 02059789 · 9 mg/mL · injection solution-10mL Vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-23 — choose a marketed DIN from the same-category list.Discontinued February 23, 2016 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-23 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2016-02-23 — choose a marketed DIN from the same-category list.
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Aredia · DIN 02059789 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-07-12 Health Canada: Cancelled post market since 2016-02-23 · brand AREDIA 90MG · ATC M05BA03 PAMIDRONIC ACID · form Powder for solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 90 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Aredia: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02059789)

Source record
DIN 02059789: Aredia Raw flags: sec3=Y, sec3b=Y Item: 920000564; group id 947; item number 2253; lccId None; manufacturer id NOV Source form: Inj Sol-10mL Vial; strength: 9mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02059789 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19018
Interchangeable products
Pamidronate Disodium Omega · DIN 02249685 · $260.3300 Pamidronate Disodium for Injection · DIN 02246599 · $260.3300
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02059789
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 23, 2016 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M05B, M05BA): coverage varies; not interchangeable

  • Alendronate (Fosamax): general benefit, not a benefit
  • Risedronate (Actonel DR): general benefit, not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, not a benefit
  • Etidronate (Didronel): limited Use 236, 237, not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE  Tumor-induced hypercalcemia following adequate saline rehydration. Prior to treatment with Pamidronate Disodium for Injection (pamidronate disodium), renal excretion of excess calcium should be promoted by restoring and maintaining adequate fluid balance and urine output.  Conditions associated with increased osteoclast activity: predominantly lytic bone metastases and multiple myeloma.  Symptomatic Paget's disease of bone. https://pdf.hres.ca/dpd_pm/00050142.PDF PM date: March 12, 2019 Source product: PAMIDRONATE DISODIUM FOR INJECTION; DIN 02246597; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Pamidronate Disodium for Injection · DIN 02246599 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246599

Check this DIN again

Pamidronate Disodium Omega · DIN 02249669 Shortage status: active shortage (reported 2013-01-01, last updated 2017-10-05) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249669

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Pamidronate (Many Generics)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient.

Ministry criteria corpus 2025-01-01; page 474

Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL
For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient.
Standard Approval Duration: 12 months
474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary.
Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s:
1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND
2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria.
i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided.
Standard Approval Duration: 12 months
Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal.
Post-transplant Drugs

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.